Healthspan trials need measures that can show meaningful change
LinkedIn caption
📊 Healthspan trials need measures that can show meaningful change
At ARDD 2026, Andrew Brack described ARPA-H’s ProSPR work on functional measures anchored in intrinsic capacity. The official recap explains why this matters: mortality endpoints take time, while many molecular biomarkers still need stronger links to clinical outcomes.
💡 ProSPR is combining longitudinal datasets with an at-home measurement approach and pursuing qualification of a clinical outcome assessment that other sponsors could use. The aim is shared trial infrastructure that helps researchers evaluate whether an intervention preserves abilities people rely on in daily life.
#ARDD2026 #ClinicalTrials #Healthspan
X caption
📊 Andrew Brack described ProSPR at #ARDD2026: shared functional measures and intrinsic-capacity tools could help healthspan trials connect biological changes with meaningful everyday abilities. The goal is a stronger bridge between molecular signals and clinical outcomes.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
